Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation

被引：24
作者：
Abouchedid R. [1 ,2 ]
Ho J.H. [1 ,2 ]
Hudson S. [3 ]
Dines A. [1 ]
Archer J.R.H. [1 ,4 ]
Wood D.M. [1 ,4 ]
Dargan P.I. [1 ,4 ]
机构：
[1] Department of Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London
[2] Emergency Department, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London
[3] LGC Ltd, Fordham, Cambridgeshire
[4] Faculty of Life Sciences and Medicine, King’s College London, London
来源：
Journal of Medical Toxicology | 2016年 / 12卷 / 4期
关键词：
5F-AKB-48; 5F-PB-22; Novel psychoactive substances; Recreational drug toxicity; Synthetic cannabinoid receptor agonist;
D O I：
10.1007/s13181-016-0571-7
中图分类号：
学科分类号：
摘要：
Introduction: Synthetic Cannabinoid Receptor Agonists (SCRAs) are the largest group of new psychoactive substances reported to the European Warning System and the United Nations Office on Drugs and Crime to date. The heterogeneous nature and speed of diversification of these compounds make it challenging to accurately characterise and predict harms of these compounds in pre-clinical studies, ahead of their appearance. Case Report: We report the case of a 19-year-old female who purchased three products from a headshop: two new psychoactive substances (sachets of “cannabis tea” and “mushroom tea”) as well as two LSD blotters. After the “cannabis tea” was smoked and the two LSD blotters and “mushroom tea” were ingested, the patient became tachycardic (HR 128), developed seizures, agitation, visual hallucinations as well as suspected serotonergic toxicity (sustained ankle clonus 20–30 beats) 1–2 hours after use. She was treated with 1 mg of intravenous midazolam. Symptoms/signs resolved within 13 hours. No further supportive care was required. Plasma, blood, and urine samples confirmed the presence of two SCRAs: 5FAKB-48 and 5F-PB-22. The patient also reported therapeutic use of both fluoxetine and citalopram for depression. Discussion: To the best of our knowledge, this is the first case report of non-fatal intoxication with 5F-AKB-48 with analytical confirmation and exposure times. It also highlights the difficulties in understanding the pattern of toxicity of certain SCRAs in the context of psychotropic medications/co-morbid mental illness. © 2016, American College of Medical Toxicology.
引用
收藏
页码：396 / 401
页数：5
相关论文
共 34 条
[1]  
European Drug Report (Trends and Developments), (2015)
[2]  
Mechoulam R., Gaoni Y., A total synthesis of D1-delta-1-tetrahydrocannabinol, the active constituent of hashish, J Am Chem Soc, 87, pp. 3273-3275, (1965)
[3]  
Wagner J.A., Jarai Z., Batkai S., Kunos G., Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors, Eur J Pharmacol, 423, pp. 203-210, (2001)
[4]  
Calignano A., Katona I., Desarnaud F., Giuffrida A., La Rana G., Mackie K., Freund T.F., Piomelli D., Bidirectional control of airway responsiveness by endogenous cannabinoids, Nature, 408, pp. 96-101, (2000)
[5]  
De Petrocellis L., Melck D., Bisogno T., Di Marzo V., Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders, Chem Phys Lipids, 108, pp. 191-209, (2000)
[6]  
Wilson R.I., Nicoll R.A., Endocannabinoid signaling in the brain, Science, 296, pp. 678-682, (2002)
[7]  
Tomida I., Pertwee R.G., Azuara-Blanco A., Cannabinoids and glaucoma, Br J Ophthalmol, 88, pp. 708-713, (2004)
[8]  
Maccarrone M., CB2 receptors in reproduction, Br J Pharmacol, 153, pp. 189-198, (2008)
[9]  
Le Foll B., Goldberg S.R., Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence, JPET, 312, pp. 875-883, (2005)
[10]  
Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G.K., Pasquali R., Pagotto U., Endogenous cannabinoid system as a modulator of food intake, Int J Obes, 27, pp. 289-301, (2003)
1234